Richards, Merrill & Peterson, Inc. Ocuphire Pharma, Inc. Transaction History
Richards, Merrill & Peterson, Inc.
- $191 Billion
- Q4 2024
A detailed history of Richards, Merrill & Peterson, Inc. transactions in Ocuphire Pharma, Inc. stock. As of the latest transaction made, Richards, Merrill & Peterson, Inc. holds 70 shares of OCUP stock, worth $68. This represents 0.0% of its overall portfolio holdings.
Number of Shares
70Holding current value
$68% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding OCUP
# of Institutions
45Shares Held
5.22MCall Options Held
14.1KPut Options Held
800-
Bios Capital Management, LP Fort Worth, TX2.48MShares$2.43 Million3.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA992KShares$972,3560.0% of portfolio
-
Geode Capital Management, LLC Boston, MA314KShares$307,7040.0% of portfolio
-
Voss Capital, LLC Houston, TX191KShares$187,1380.02% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il176KShares$172,2570.0% of portfolio
About Ocuphire Pharma, Inc.
- Ticker OCUP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,579,800
- Market Cap $20.2M
- Description
- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...